LGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders

Details for Australian Patent Application No. 2008282863 (hide)

International Classifications

Event Publications

4 February 2010 PCT application entered the National Phase

PCT publication WO2009/017679 Priority application(s): WO2009/017679

11 February 2010 Amendment Made

The nature of the amendment is: Amend the co-applicant name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

11 February 2010 Corrigenda

PCT applications that have entered the National Phase - Name Index Under the name Merck & Co., Inc.; Pierre Fabre Medicament, Application No. 2008282863, under INID (54) correct the title to read IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders. Specifications Republished The following specifications contained errors when advertised OPI, Specifications Republished Accepted or Certified. They have been reissued on the AU-A or AU-B CD-ROM of this Journal dat

4 October 2012 Alteration of Name

The name of the applicant has been altered to Pierre Fabre Medicament; Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.